Christopher D. King

PharmAkea, Inc. develops small molecule drug candidates against protein targets involved in fibro proliferative diseases. It discovers and develops small molecule therapeutics directed at cancer and fibrotic diseases. The company was founded by John Howard Hutchinson, Kevin Holme, and Jilly Evans in 2012 and is headquartered in San Diego, CA.

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of vascular immune-mediated inflammatory diseases. Its product, the Destruction of Arteriosclerotic Blockages by laser Radiation Ablation (DABRA) laser and single-use catheter, together referred to as DABRA, is used as a tool in the treatment of peripheral artery disease which commonly occurs in the legs. The company was founded by Dean Irwin and Melissa Burstein on September 4, 2002 and is headquartered in Fort Mill, SC.